- Telehealth Visits
- Insurance plan information
Thomas G. Martin, MD
Hematology Oncology • Myeloma- Telehealth Visits
- Insurance plan information
Thomas G. Martin, MD
Hematology Oncology • Myeloma- Telehealth Visits
- Insurance plan information
On this page
About me
A leading expert in hematology-oncology, Dr. Thomas Martin is associate director of UCSF's myeloma program and director of the unrelated donor transplantation programs for adults at UCSF Medical Center.
Martin is clinical research director of hematologic malignancies (blood cancers) at the UCSF Helen Diller Family Comprehensive Cancer Center. His research interests include developing treatments for myeloma and leukemia as well as expanding the use of bone marrow transplants. He has a special interest in umbilical cord blood transplants, and he is involved in efforts to improve outcomes for patients who have transplants from unrelated donors.
Martin earned an undergraduate degree at Cornell University and his medical degree at the University of Connecticut School of Medicine. After a medical residency at Harbor-UCLA Medical Center, he completed a fellowship in hematology-oncology at UCSF. In 1999, he joined MD Anderson Cancer Center as an assistant professor of medicine. In 2001, he returned to UCSF.
Education & training
Board certification
- Hematology, American Board of Internal Medicine
Fellowship
- Hematology, UCSF Medical Center - OMAG
Residency
- Internal Medicine, Harbor / UCLA Medical Center
Internship
- Internal Medicine, Harbor / UCLA Medical Center
Degree
- MD, University of Connecticut School of Medicine
My expertise
Specialties
- Hematology Oncology
- Myeloma
Conditions
Treatments
Locations
My research
Clinical trials
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple MyelomaOpens in a new window
Recruiting
Safety will be evaluated for the population of participants who received at least one dose of study drug. Treatment-emergent AEs will be graded by the Common…CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple MyelomaOpens in a new window
Recruiting
Proportion of participants with treatment-emergent adverse events of CAR-T in RRMM as graded by National Cancer Institute Common Terminology Criteria for…
Publications
Showing 1-6 of 92 reviews
- January 30, 20265 out of 5 Stars
Love Dr Martin !!!I truly feel blessed to be his patient
- January 22, 20265 out of 5 Stars
Having Dr. Martin guiding my Cx care is one of the greatest blessings of my life! I am overwhelmingly grateful to hime.
- January 6, 20265 out of 5 Stars
Dr Martin is the GOAT. !!!
- December 19, 20255 out of 5 Stars
Excellent visit w Dr Martin. As always, he listened to my concerns and offered options. I chose how to proceed. He scheduled my upcoming medical tests while we spoke and made it all very seamless. I always recommend Dr. Martin for his excellence and expertise.
- December 12, 20255 out of 5 Stars
Best doctor ever!
- December 6, 20255 out of 5 Stars
DR. MARTIN HAS BEEN MY DR. SINCE 2000 & HE IS INCREDIBLE!!!!!!
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.